TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology Meeting
The ability of TG-0054 to cause mobilization of EPC may support its use in other areas besides hematology. For instance the body may be able to grow new blood vessels around the areas of ischemia.